Retatrutide 10mg / 20mg / 30mg / 40mg / 60mg

Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder in 20mg, 30mg, 40mg and 60mg vials, each batch is verified to 99%+ purity by RP-HPLC and mass spectrometry.

Classification: Retatrutide (LY3437943) — a synthetic 39 amino-acid triple-agonist peptide with a C20 fatty-diacid moiety, engineered to activate three incretin/glucagon-family receptors in a single molecule.

Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.

This summary describes published preclinical and, where applicable, clinical research. It is not a medical claim and does not describe or endorse any human use of the compound as sold by Peptides UK 4U.

Published research characterises retatrutide as an agonist at the GLP-1 receptor, the GIP receptor and the glucagon receptor. Preclinical and early clinical studies investigate the metabolic signalling consequences of simultaneous activation of all three pathways — a mechanism not shared by single- or dual-agonist analogues.

Reconstitute with bacteriostatic water in a sterile environment; the fatty-acid modification gives Retatrutide a long in-solution stability profile relative to native GLP-1. Prepare working aliquots to minimise freeze-thaw cycles.

Storage & stability

• Lyophilised vials: store below -18°C, protected from light.
• Reconstituted solution: refrigerate at 2–8°C.
• Avoid repeated freeze-thaw cycles to preserve peptide integrity.

For in vitro research use only. We do not provide preparation, dosing or usage guidance.

Peptide Type

Triple receptor agonist (GLP-1 / GIP / Glucagon)

Sequence length

39 amino acids

Molecular weight

≈4,731 Da

Form

Lyophilised powder

Quantity

20mg, 30mg, 40mg or 60mg per vial

Purity

99%+ by RP-HPLC + MS

Solubility

Water / bacteriostatic water

Research code

LY-3437943

Certificate of Analysis: Batch-specific COA available. View COAs.

• Coskun T et al., Cell Metabolism 34(9):1234–1247 (2022) — LY3437943 discovery and preclinical
• Jastreboff AM et al., NEJM 389(6):514–526 (2023)
• Rosenstock J et al., The Lancet 402(10401):529–544 (2023)

References are provided for educational context. Citation does not imply endorsement of any specific use.